Ren J-S, Kamangar F, Qiao Y-L, Taylor P R, Liang H, Dawsey S M, Liu B, Fan J-H, Abnet C C
Cancer Institute of the Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Gut. 2009 May;58(5):636-42. doi: 10.1136/gut.2008.168641. Epub 2009 Jan 9.
Low serum pepsinogen I (PGI) and low pepsinogen I/pepsinogen II ratio (PGI/II ratio) are markers of gastric fundic atrophy. We aimed to prospectively test the association between serum PGI/II ratio and risks of gastric non-cardia adenocarcinoma, gastric cardia adenocarcinoma, and oesophageal squamous cell carcinoma (OSCC).
Case-cohort study nested in a prospective cohort with over 15 years of follow-up.
Rural region of the People's Republic of China.
Men and women aged 40-69 years at study baseline.
Adjusted hazard ratios and 95% confidence intervals for the association between serum PGI/II ratio and cancer risk.
Compared to subjects with PGI/II ratio of >4, those with <or=4 had hazard ratios (HRs) (95% CIs) of 2.72 (1.77 to 4.20) and 2.12 (1.42 to 3.16) for non-cardia and cardia gastric adenocarcinomas, respectively. Risk of both cancers was also increased when we used other cut points ranging from 3 to 6, or quartile models, or nonlinear continuous models. Risk of OSCC was marginally increased in those with PGI/II ratio <or=4, with HR (95% CI) of 1.56 (0.99 to 2.47), but quartile models and continuous models showed no increased risk. The nonlinear continuous models suggested that any single cut point collapsed subjects with dissimilar gastric adenocarcinoma risks, and that using cut points was not an efficient use of data in evaluating these associations.
In this prospective study, we found similar and significantly increased risks of non-cardia and cardia gastric adenocarcinomas in subjects with low PGI/II ratio but little evidence for an association with the risk of OSCC.
血清胃蛋白酶原I(PGI)水平低和胃蛋白酶原I/胃蛋白酶原II比值(PGI/II比值)低是胃底萎缩的标志物。我们旨在前瞻性地检验血清PGI/II比值与胃非贲门腺癌、胃贲门腺癌和食管鳞状细胞癌(OSCC)风险之间的关联。
嵌套于一项有超过15年随访的前瞻性队列中的病例队列研究。
中华人民共和国农村地区。
研究基线时年龄在40 - 69岁的男性和女性。
血清PGI/II比值与癌症风险之间关联的调整后风险比和95%置信区间。
与PGI/II比值>4的受试者相比,PGI/II比值≤4的受试者发生非贲门和贲门胃腺癌的风险比(HRs)(95%CI)分别为2.72(1.77至4.20)和2.12(1.42至3.16)。当我们使用3至6的其他切点、四分位数模型或非线性连续模型时,两种癌症的风险也会增加。PGI/II比值≤4的受试者患OSCC的风险略有增加,HR(95%CI)为1.56(0.99至2.47),但四分位数模型和连续模型未显示风险增加。非线性连续模型表明,任何单个切点都会将具有不同胃腺癌风险的受试者归为一组,并且在评估这些关联时使用切点并不是有效利用数据的方法。
在这项前瞻性研究中,我们发现PGI/II比值低的受试者发生非贲门和贲门胃腺癌的风险相似且显著增加,但几乎没有证据表明其与OSCC风险有关联。